FY2025 EPS Estimates for DRUG Boosted by Cantor Fitzgerald

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Bright Minds Biosciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($0.64) for the year, up from their previous forecast of ($0.87). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences’ FY2026 earnings at ($0.75) EPS.

Other equities analysts have also issued research reports about the stock. Cowen began coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a “buy” rating for the company. TD Cowen assumed coverage on shares of Bright Minds Biosciences in a research report on Tuesday, May 13th. They set a “buy” rating for the company. Chardan Capital restated a “buy” rating and set a $80.00 price target on shares of Bright Minds Biosciences in a research note on Wednesday, May 21st. Wall Street Zen cut shares of Bright Minds Biosciences from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $85.00 price objective on shares of Bright Minds Biosciences in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $83.25.

Bright Minds Biosciences Price Performance

Shares of Bright Minds Biosciences stock opened at $28.38 on Wednesday. The firm has a market cap of $199.91 million, a PE ratio of -166.93 and a beta of -5.75. Bright Minds Biosciences has a 1 year low of $0.93 and a 1 year high of $79.02. The stock has a fifty day moving average price of $30.38 and a 200-day moving average price of $34.93.

Bright Minds Biosciences (NASDAQ:DRUG) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.10.

Institutional Trading of Bright Minds Biosciences

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in Bright Minds Biosciences in the 4th quarter valued at approximately $238,000. Millennium Management LLC bought a new position in shares of Bright Minds Biosciences in the fourth quarter worth $1,454,000. RA Capital Management L.P. purchased a new position in shares of Bright Minds Biosciences in the fourth quarter valued at $16,599,000. Vivo Capital LLC bought a new stake in shares of Bright Minds Biosciences during the 4th quarter valued at $9,062,000. Finally, Walleye Capital LLC bought a new stake in shares of Bright Minds Biosciences during the 4th quarter valued at $3,717,000. 40.52% of the stock is currently owned by hedge funds and other institutional investors.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.